Psyence Biomedical (PBMWW) Stock Analysis

What Psyence Biomedical does

Psyence Biomedical Ltd. focuses on developing psychedelic medications derived from botanical psilocybin. The company is also investigating the use of natural psilocybin to alleviate adjustment disorder in patients with incurable cancer who are undergoing palliative care. Its primary product candidate, PEX010, is a capsule containing naturally sourced psilocybin, which is currently undergoing a Phase IIb clinical study. PEX010 aims to treat anxiety, depression, and related conditions such as post-traumatic stress disorder, stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial, examining PEX010's efficacy in psilocybin-assisted psychotherapy for adjustment disorder caused by incurable cancer. Headquartered in Toronto, Canada, the company operates as a subsidiary of Psyence Group Inc.

Key metrics

ETFs linked to PBMWW

Broad-market and Healthcare sector ETFs an investor holding Psyence Biomedical is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PBMWW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Psyence Biomedical?

Psyence Biomedical trades under the ticker PBMWW on NASDAQ.

Which exchange is PBMWW listed on?

PBMWW is listed on NASDAQ.

What sector does Psyence Biomedical operate in?

Psyence Biomedical is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PBMWW in a portfolio?

PortView shows PBMWW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.